002007 Hualan Biological Engineering, Inc.
- 16.43
- +0.35+2.18%
Hualan Biological Engineering, Inc. News
Hualan Biological Engineering Inc.'s (SZSE:002007) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Are Investors Undervaluing Hualan Biological Engineering Inc. (SZSE:002007) By 42%?
Hualan Biological Engineering, Inc. (002007.SZ): The company has obtained a single-sourced plasma collection license.
On December 4, Gelonghui reported that hualan biological engineering, inc. (002007.SZ) announced that on December 4, 2024, the company's wholly-owned subsidiary, hualan biological engineering chongqing co., ltd., received the "Plasma Collection License" issued by the Chongqing Municipal Health Committee for the hualan plasma collection station in Wushan County, Chongqing (hereinafter referred to as "Wushan Plasma Station"). The Wushan Plasma Station can officially begin plasma collection from the date it obtains the "Plasma Collection License." The operation of plasma collection at the Wushan Plasma Station will help enhance the company's supply capacity of raw plasma, which will have a positive impact on the company's long-term development.
Hualan Biological Engineering's Unit Gets Certificate for Cancer Drug's Registration
hualan biological engineering, inc. (002007.SZ): The genetic company has received the pharmaceutical registration certificate for the Ramucirumab injection.
On November 21, 2023, Hualan Biological Engineering, Inc. (002007.SZ) announced that on November 21, 2024, its affiliated company Hualan Gene Engineering Co., Ltd. (referred to as "Gene Company") obtained the "Drug Registration Certificate" for Bevacizumab Injection issued by the National Medical Products Administration. The Gene Company has been approved for Anbeiyou (Bevacizumab Injection), which is mainly used for the treatment of advanced, metastatic, or recurrent non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer, with the original manufacturer being Roche.
Hualan Biological Engineering (SZSE:002007) Sheds CN¥1.8b, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Earnings Miss: Here's What Hualan Biological Engineering Inc. (SZSE:002007) Analysts Are Forecasting For Next Year
Hualan Biological Engineering, Inc.: Third-quarter report of 2024.
hualan biological engineering, inc. (002007.SZ) released its performance for the first three quarters, with a net income of 0.924 billion yuan, a year-on-year decrease of 13.46%.
hualan biological engineering, inc. (002007.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Express News | Hualan Biological Engineering Q3 Net Profit Down 10.6% Y/Y
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Hualan Biological Engineering Inc.'s (SZSE:002007) Intrinsic Value Is Potentially 89% Above Its Share Price
Hualan Biology: 2024 Semi-Annual Report
Hualan Biology: Summary of the 2024 Semi-Annual Report
hualan biological engineering, inc. (002007.SZ): net income of 0.44 billion yuan in the first half of the year, a year-on-year decrease of 16.42%
GeLongHui August 29th | Hualan Biological Engineering, Inc. (002007.SZ) released its semi-annual report for 2024, with a reported revenue of 1.653 billion yuan for the reporting period, a year-on-year increase of 4.26%; net income attributable to the shareholders of the listed company was 0.44 billion yuan, a year-on-year decrease of 16.42%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.363 billion yuan, a year-on-year decrease of 8.73%; basic earnings per share was 0.2406 yuan.
Express News | Hualan Biological Engineering H1 Net Profit Down 16.4% Y/Y
Hualan Biological to Set Up Plasma Stations in Two Chinese Counties
Hualan Biological Engineering Inc.'s (SZSE:002007) Market Cap Dropped CN¥1.3b Last Week; Individual Investors Bore the Brunt
Sinolink Securities: Further consolidation of the blood product industry through external mergers and acquisitions and product diversification.
Referring to the development process of leading overseas blood product companies, external mergers and acquisitions, new product development, and efficiency improvement are three important development routes. In recent years, domestic blood product industry mergers and acquisitions have continued to take place, and the concentration of the industry has shown a further upward trend.
Guolian Securities: Supply and demand boost, domestic blood product penetration rate is expected to continue to rise.
The per capita use of blood products in China is less than one-fourth that of developed countries such as the USA, and the demand is showing an increasing trend. As the supply of plasma increases and clinical awareness improves in the future, China's penetration rate is expected to continue to improve.
No Data